Matches in DBpedia 2016-04 for { ?s ?p "Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.On December 23rd 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Aplindore comment "Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.On December 23rd 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger.".
- Q4779987 comment "Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.On December 23rd 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger.".